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Abacavir (ABC), a nucleoside reverse transcriptase in-
hibitor (NRTI), combined with lamivudine (3TC), has a 
better short- and long-term outcome than 3TC com-
bined with zidovudine (ZDV) as first-line HIV therapy.1,2 
In addition, children failing ABC/3TC-based first-line 
therapy do not select thymidine NRTI-related muta-
tions, allowing for better choice in second-line thera-
py.2 With current first-line options, both first-line (sta-
vudine (d4T)) and second-line therapy (ZDV) include a 
thymidine-based NRTI, thus compromising second-line 
regimens.3-5 In well-selected children, ABC is also an 
important drug in second-line and salvage therapy.6
Of all the NRTIs, ABC is associated with the lowest rate 
of mitochondrial dysfunction. Types of dysfunction in-
clude lactic acidosis, peripheral neuropathy and lipo-at-
rophy. Substitution of d4T for ABC improves mitochon-
drial indices and reduces adipocyte apoptosis.7 In adults, 
switching from d4T to ABC was superior to switching 
from d4T to ZDV.8 In older children, once-daily use of 
ABC has also been shown to be effective, thereby fa-
cilitating adherence and improving patient satisfaction, 
particularly when all drugs are given once daily.9,10
Despite these advantages, ABC is rarely used as part of 
first-line therapy in South Africa owing to cost. Tenofo-
vir, commonly used in adults experiencing NRTI adverse 
events, is not licensed for children. With large cohorts 
of children now on antiretroviral therapy for long peri-
ods of time, increased use of ABC is likely as NRTI ad-
verse events become apparent. Currently, the National 
Department of Health permits using ABC when there 
have been adverse events related to other NRTIs. 
Of concern is the severe and life-threatening hypersen-
sitivity reaction (HSR) that occasionally occurs, neces-
sitating permanent discontinuation of ABC.
ABC HSR has been reported in adults and children. The 
prevalence in clinical trials varies.11 In a European trial 
of first-line therapy, where 92 children were initiated 
on ABC, 4 (4.3%) terminated ABC for adverse reactions, 
1 case (1%) being considered an HSR. There is clear 
heterogeneity in risk according to ethnic groups, with 
Caucasians at higher risk and a 40% reduction in risk 
for African Americans. In the ARROW study of >1 200 
HIV-infected children in Uganda and Zimbabwe, HSR 
was reported in 0.2% of the children.12
Other factors that may be protective are male sex and 
more advanced disease. However, this assessment was 
performed before identification of the genetic link to 
HSR.13 
HLA-B*5701 AND HSR
An association with ABC HSR was described with HLA-
B*5701, HLA-DR7 and HLA-DQ3. If all three markers are 
present, the positive predictive value for HSR is 100% 
with a negative predictive value of 97%. HLA-B*5701 
alone is highly predictive.14 
It is clear that the varied distribution of the HLA-B*5701 
genotype is responsible for variability of the risk of ABC 
HSR between races and studies.15 Studies from the USA 
indicated that this mutation is more prevalent among 
white and Hispanic persons than African Americans.16 
In Korea the HLA-B*5701 genotype and ABC HSR are 
rare.17
In the PREDICT-1 study, where patients with HLA-
B*5701 did not receive ABC, 3.4% of patients given 
ABC were diagnosed with HSR but no cases could be 
confirmed with patch testing (a research tool only).18 
Prospective screening for HLA-B*5701 in patients and 
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Abacavir, a nucleoside reverse transcriptase inhibitor, is useful in first- and second-line HIV therapy and as a 
substitute for stavudine and zidovudine when toxicity is a problem. Although it is safe and well tolerated, a life-
threatening hypersensitivity reaction can occur. The risk for developing this reaction relates to the presence of 
specific genotypes, especially HLA-B*5701. 
EPiDEMiOLOGY AND ESTiMATiON OF RiSK FOR HSR
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avoidance of ABC in positive patients is effective in re-
ducing HSR, and this is now the standard of care in the 
First World. Over-diagnosis of HSR is well documented 
in the absence of testing.19 A reduction in confirmed 
cases occurs when routine testing is performed.18
Despite the availability of testing and the recommen-
dation to test, there is a debate as to the cost effec-
tiveness and cost benefit of testing in ethnic groups 
where HLA-B*5701 is not prevalent.17
There are no data on the prevalence of HLA-B*5701 in 
the various South African ethnic groups. Full genetic 
screening for HLA-B*5701 is very costly. Cheaper meth-
ods involving PCR for small sequences of the gene are 
currently under review. Although full testing is avail-
able in South Africa, patients in the public sector do 
not have access. We recommend that testing be offered 
to all patients where affordable, regardless of ethnic 
group, until more information is available. However, 
it is reasonable to use ABC without prior screening if 
there is no alternative. 
It is important to remember that HSR has been report-
ed in patients negative for HLA-B*5701.20 In patients 
in whom HSR reaction was diagnosed and who subse-
quently tested negative for HLA-B*5701, ABC remains 
contraindicated.
Diagnosis of ABC HSR is complicated by its subtle initial 
features. Also, other drugs such as trimethoprim-sul-
famethoxazole, nevirapine and efavirenz are known to 
cause hypersensitivity and should be recognised. Dis-
tinguishing the ABC HSR from other drug-related ad-
verse events, intercurrent infections and even immune 
reconstitution inflammatory syndrome may be particu-
larly difficult when ABC is used as first-line therapy, 
as all drugs are initiated simultaneously. In addition, 
ABC initiation may lead to symptoms that are similar 
but not related to HSR, including nausea and vomiting, 
fever and rash. These reactions are usually mild. 
Ninety-four per cent of patients who experience HSR do 
so within 6 weeks after initiation of therapy. The me-
dian time to onset is 11 days, but symptoms can start 
on the first day and have been reported up to 318 days 
later. ABC HSR has occurred in patients who interrupted 
therapy without having had hypersensitivity and subse-
quently restart, but this is believed to be rare.11,21 A single 
case of ABC HSR after switching from twice daily to once 
daily administration has also been reported.22 Vigilance 
for the duration of ABC exposure is required.
The ABC HSR is a multi-organ process manifesting 
signs or symptoms from at least two of the following 
groups: 
n  Fever is the most common manifestation of ABC 
HSR, occurring in 80% of cases. Chills have been 
reported to accompany fever.
n  Rash is experienced by 70% of cases, and pruritus 
can also occur. In contrast to the rash caused by 
non-NRTIs and sulphonamides, it is often mild and 
may go unnoticed by patients. When rash occurs in 
the absence of other features of HSR, ABC should 
not be discontinued.
n  Gastro-intestinal symptoms such as nausea, vom-
iting, diarrhoea and abdominal pain are all features 
of HSR but may also occur in the absence of HSR, 
particularly when ABC is used with ZDV. Therefore, 
as with rash, patients with isolated gastro-intestinal 
symptoms should not discontinue ABC but should 
be followed up closely.
n  Constitutional symptoms include fatigue, myalgias 
and generalised malaise.
n  Respiratory symptoms occur in 18% of cases and 
include dyspnoea, cough and pharyngitis. Symptoms 
may be difficult to distinguish from those caused by 
influenza and other respiratory viruses. Respiratory 
symptoms together with abdominal symptoms sug-
gest HSR rather than influenza or other respiratory 
illness.23 
Clusters and combinations of symptoms are important 
in the diagnosis of ABC HSR. Table I illustrates the fre-
quency of some combinations.11,24
With ABC HSR, there is an accentuation of symptoms 
in the hours immediately after the dose and worsen-
ing of symptoms with each subsequent dose. A number 
of case reports illustrate the varied clinical presenta-
tion, with Kawasaki-like illness, prominent exanthema 
and even disseminated intravascular coagulation being 
seen.25-29
If ABC is not terminated, or if it is re-initiated after 
temporary cessation, the HSR will progress to hypoten-
sion, renal dysfunction, bronchospasm and ultimately 
death.11 
Abnormal laboratory findings may include leucopenia, 
anaemia and thrombocytopenia, as well as elevations 
Systems and combinations %
3 or 4 organ systems 49
Fever and rash 20
Fever and GIT   8
Skin and GIT   3
Skin and constitutional   3
Other combinations 17
GIT = gastro-intestinal.
TABLE i. FREQUENCY OF SYMPTOM COMBiNATiONS 
iN ABACAViR HYPERSENSiTiViTY (ADAPTED FROM 
CLAY24)
CLiNiCAL FEATURES AND DiAGNOSiS OF ABC HSR
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in transaminases, urea, creatinine and lactate dehy-
drogenase (LDH). Eosinophilia is usually absent.11 Patch 
testing is currently only a research tool.
Termination of therapy is followed by rapid improve-
ment in the symptoms.
Rechallenging with ABC leads to anaphylaxis and 
should be avoided even in cases where there was diag-
nostic uncertainty.
In Table II we set out the features of the first 3 cases 
of suspected HSR seen at the Tygerberg Children’s Hos-
pital Family Clinic for HIV. Of note is that HSR was 
documented in children across the racial spectrum. In 
all patients there was progression of symptoms over 
time and in 1 case there was a clear increase in sever-
ity associated with dosing. All children had abdominal 
symptoms and nonspecific rash. In these cases, child-
ren were stable on other ART drugs as they had all 
switched to ABC because of d4T toxicity.
On commencement of ABC, patients should be coun-
selled in detail about the possible signs of HSR and be 
advised to contact their care provider should any occur. 
To avoid confusion, therapy should not be initiated in 
patients with intercurrent symptoms.
It is advisable for patients to discuss symptoms early 
with the clinician rather than terminating therapy 
without consultation. Where termination without con-
sultation occurs, ABC cannot be reinitiated. Patients 
should also be made aware of the special ‘patient alert 
card’ that comes in the packaging. This card should be 
presented to any health care provider who sees the 
child, especially when care is not given by the usual 
provider. Providers at emergency facilities may be less 
familiar with this condition, and where possible con-
tact information for the usual care provider should be 
supplied as well. 
Deciding whether to terminate therapy in a patient 
with suggestive symptoms can be difficult given the 
very nonspecific nature of the presentation. A detailed 
medical history should be obtained. The following 
should be considered:
n  When was ABC initiated? In the case of ABC HSR, 
usually within the past 6 weeks. 
n  Are two or more systems involved?
n  Do the symptoms increase with each dose?
n  Are the symptoms exacerbated just after the dose?
n  Do the symptoms fit into the well-recognised clus-
ters?
n  What other medications/medication is the patient 
taking, and what was the timing of their initiation 
related to the ABC?
If patients present with mild symptoms and it is not 
clear whether symptoms are due to HSR, the clinician 
may consider allowing an additional dose. The patient 
should be able to report back, or hospitalisation may 
be required for observation. If symptoms worsen, ABC 
should be terminated immediately and permanently. If 
symptoms do not worsen, ABC can be carefully con-
 Case 1 Case 2 Case 3
Race White Coloured Black
Age (years) 9 5 10
Gender Female Male Male
Time to onset of symptoms <1 day 9 days 2 months
Accentuation with dose Yes Uncertain Uncertain 
Increasing severity Yes Yes Yes
Time after onset to  
presentation to TCH (days) 1 5 3 
Fever No Yes No
Rash Blotchy, erythematous on  Extensive maculopapular Fine papular rash on 
 neck and hands  on trunk, arms and legs the chest 
 Papules on the trunk and  Exanthema in mouth
 left arm Non-purulent conjunctivitis
Gastrointestinal  Loss of appetite  Nausea Abdominal pain and
 Epigastric and right upper  Loose stools tenderness 
 quadrant tenderness  Vomiting 
   Loss of appetite 
Constitutional Myalgias  Lethargy Weight loss (1 kg)
 Malaise
Respiratory No No Cough 
   Red throat
Number of systems affected 3 4 4
Time to resolution 48 hours 5 days 2 - 3 days
HLA-B*5701 Negative – tested after  Positive – tested after  Negative – tested after  
 the HSR the HSR the HSR 
TABLE ii. CLiNiCAL FEATURES iN 3 CHiLDREN DiAGNOSED WiTH ABC HSR AT TYGERBERG CHiLDREN’S HOSPiTAL 
AFTER A SiNGLE DRUG SUBSTiTUTiON OF STAVUDiNE FOR LiPO-ATROPHY
MANAGEMENT OF PATiENTS iNiTiATiNG ABC
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tinued while other possible reasons for the patient’s 
symptoms are investigated. When the diagnosis is 
thought to be clear or there is sufficient concern, ABC 
should be terminated immediately and permanently.
Hospitalisation and special investigations will depend 
on the severity of symptoms. Corticosteroids do not 
prevent or alter the natural history of ABC HSR.30 The 
reaction usually improves within 48 hours.
Clinicians treating children need to be very aware of 
the usefulness of ABC. Although there is no informa-
tion on the prevalence of either ABC hypersensitivity or 
HLA-B*5701 in South African children, available data 
suggest that black children are at lower risk than Cau-
casian children, with no data on children of mixed race. 
Although screening for HLA-B*5701 is recommended 
and will prevent cases, research is needed to assess its 
cost effectiveness in the South African public health 
setting. 
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